Stephens lowered the firm’s price target on Akoya Biosciences to $14 from $16 and keeps an Overweight rating on the shares. The firm noted that the company reported a Q2 revenue beat, adding that if you strip out a $2M non-routine spoilage charge from COGS and $2M in severance costs from OpEx, GM and operating loss would have also beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKYA:
- Akoya Biosciences price target lowered to $11 from $14 at BTIG
- Akoya Biosciences backs FY23 revenue view $95M-$98M, consensus $96.38M
- Akoya Biosciences reports Q2 EPS (51c), consensus (44c)
- Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
- Akoya announces 1,000 peer-reviewed publications citing Spatial Biology Tech